← Back to Screener
BioXcel Therapeutics, Inc. Common Stock (BTAI)
Price$1.20
Favorite Metrics
Price vs S&P 500 (26W)-63.47%
Price vs S&P 500 (4W)-33.33%
Market Capitalization$32.49M
All Metrics
Book Value / Share (Quarterly)$0.20
P/TBV (Annual)1.50x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)19.10%
Cash Flow / Share (Quarterly)$-2.58
Price vs S&P 500 (YTD)-32.26%
Gross Margin (TTM)74.45%
Net Profit Margin (TTM)-10887.38%
EPS (TTM)$-6.70
10-Day Avg Trading Volume1.19M
EPS Excl Extra (TTM)$-6.70
EPS (Annual)$-5.73
ROI (Annual)-97.56%
Gross Margin (Annual)74.45%
Net Profit Margin (5Y Avg)-108558.70%
Cash / Share (Quarterly)$1.27
Revenue Growth QoQ (YoY)-30.05%
ROA (Last FY)-155.62%
Revenue Growth TTM (YoY)-71.67%
EBITD / Share (TTM)$-4.41
ROE (5Y Avg)-95.18%
Operating Margin (TTM)-7859.97%
Cash Flow / Share (Annual)$-2.58
P/B Ratio5.51x
P/B Ratio (Quarterly)32.92x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)177.05x
Net Interest Coverage (TTM)-3.39x
ROA (TTM)-181.48%
EPS Incl Extra (Annual)$-5.73
Current Ratio (Annual)0.83x
Quick Ratio (Quarterly)0.74x
3-Month Avg Trading Volume1.21M
52-Week Price Return-36.81%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-1.39
P/S Ratio (Annual)50.61x
Asset Turnover (Annual)0.01x
52-Week High$8.08
Operating Margin (5Y Avg)-107317.30%
EPS Excl Extra (Annual)$-5.73
26-Week Price Return-54.72%
Quick Ratio (Annual)0.74x
13-Week Price Return-42.21%
Total Debt / Equity (Annual)1.21x
Current Ratio (Quarterly)0.83x
Enterprise Value$113.669
Asset Turnover (TTM)0.02x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.23x
Pretax Margin (Annual)-10887.38%
Cash / Share (Annual)$1.27
3-Month Return Std Dev79.61%
Net Income / Employee (TTM)$-2
ROE (Last FY)-215.83%
Net Interest Coverage (Annual)-3.39x
EPS Basic Excl Extra (Annual)$-5.73
Receivables Turnover (TTM)3.53x
Total Debt / Equity (Quarterly)16.41x
EPS Incl Extra (TTM)$-6.70
Receivables Turnover (Annual)3.53x
ROI (TTM)-126.96%
P/S Ratio (TTM)50.61x
Pretax Margin (5Y Avg)-108558.70%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$2.73
Price vs S&P 500 (52W)-71.91%
Year-to-Date Return-28.13%
5-Day Price Return12.75%
EPS Normalized (Annual)$-5.73
ROA (5Y Avg)-135.84%
Net Profit Margin (Annual)-10887.38%
Month-to-Date Return-14.18%
Cash Flow / Share (TTM)$-7.34
EBITD / Share (Annual)$-4.40
Operating Margin (Annual)-7859.97%
LT Debt / Equity (Annual)1.21x
ROI (5Y Avg)-71.53%
LT Debt / Equity (Quarterly)16.41x
EPS Basic Excl Extra (TTM)$-6.70
P/B Ratio (Annual)7.84x
Inventory Turnover (TTM)0.23x
Pretax Margin (TTM)-10887.38%
Book Value / Share (Annual)$2.73
Price vs S&P 500 (13W)-45.08%
Beta0.33x
Revenue / Share (TTM)$0.03
ROE (TTM)-309.01%
52-Week Low$1.01
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.91
3.91
3.91
3.91
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BTAIBioXcel Therapeutics, Inc. Common Stock | 50.61x | -71.67% | 74.45% | — | $1.20 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
BioXcel Therapeutics develops neuropsychiatric and immuno-oncology medicines using artificial intelligence platforms. Its FDA-approved commercial product, IGALMI, is a sublingual dexmedetomidine film for acute agitation associated with schizophrenia and bipolar I or II disorder in adults. The company is advancing additional pipeline candidates including BXCL701.